Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 1023-1025

  Freyschlag, C F ^a,b   Tuettenberg, Jochen ^a,c   Lohr, F ^a   Thome C ^a,b   Schmieder, K ^a   Seiz, M ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c SHG Klinikum Idar Oberstein   (Germany)

Author keywords

Anaplastic ependymoma; Multifocal recurrence; Temozolomide

Indexed keywords

GADOLINIUM; TEMOZOLOMIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN RADIOGRAPHY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG SAFETY; EPENDYMOMA; FEMALE; HUMAN; MICROSURGERY; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUPRATENTORIAL MALIGNANT EPENDYMOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; EPENDYMOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; RECURRENCE; SUPRATENTORIAL NEOPLASMS; TREATMENT OUTCOME;

EID: 79956100384     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rodriguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K and Koniaris LG: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 2: 340-351, 2009.
2. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK: WHO Classification of Tumours of the Central Nervous System (IARC WHO Classification of Tumours) (v. 1). World Health Organization, pp. 71-80, 2007
3. Korshunov A, Golanov A, Sycheva R and Timirgaz V: The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 6: 1230-1237, 2004. (Pubitemid 38325952)
4. Oya N, Shibamoto Y, Nagata Y, Negoro Y and Hiraoka M: Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol 1: 87-94, 2002.
5. Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE and Heideman R: Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 14: 3243-3253, 2009.
6. Hodozuka A, Hayashi Y, Annei R, Hiroshima S, Saito M, Orimoto R, Sato M and Tanaka T: Intrathecal infusion of the antineoplastic agents for meningeal dissemination. Gan To Kagaku Ryoho 6: 900-905, 2008.
7. Merchant TE and Fouladi M: Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 3: 287-299, 2005. (Pubitemid 43019484)
8. Moreno L, Bautista FJ and Zacharoulis S: Outcome of teenagers and young adults with ependymoma: the Royal Marsden experience. Childs Nerv Syst 9: 1047-1052, 2009.
9. Chamberlain MC and Johnston SK: Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer 20: 4775-4782, 2009.
10. Rehman S, Brock C and Newlands ES: A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy. Am J Clin Oncol 1: 106-107, 2006. (Pubitemid 44356727)
11. Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M and Frappaz D: Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst pp. 905-911, 2009.
12. Saito R, Kumabe T, Kanamori M, Sonoda Y and Tominaga T: Dissemination limits the survival of patients with anaplastic ependymoma after extensive surgical resection, meticulous follow up, and intensive treatment for recurrence. Neurosurg Rev 2: 185-191; discussion 191-192, 2010.
13. Stupp R, Mason WP, van den Bent MJ, Weiler M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10: 987-996, 2005. (Pubitemid 40349501)
14. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE and Lassman AB: Bevacizumab for recurrent ependymoma. Neurology 20: 1677-1680, 2009.
15. Guyotat J, Signorelli F, Desme S, Frappaz D, Madarassy G, Fevre Montange M, Jouvet A and Bret P: Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol, pp. 255-268, 2002.